Covid-19 cases in some states like Maharashtra, Kerala, Punjab, Tamil Nadu, Gujarat and Karnataka are on the rise again. These states collectively account for 85.51 per cent of the new cases, as per the latest figures

The high court also asked the Centre to explain in affidavit the rationale behind keeping strict control over class of persons who can be vaccinated against COVID-19

IT major Infosys on Wednesday said it will cover the vaccination cost for its employees in India and their family members; Bharat Biotech has announced the Phase 3 clinical trial results for its coronavirus vaccine candidate Covaxin; The COVAX initiative, co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi) and the World Health Organization (WHO), will supply 237 million doses of the AstraZeneca-Oxford COVID-19 vaccine to 142 countries by May-end. Watch this and more on News Blast.Also Read: Canada receives first shipment of 5 lakh COVID-19 vaccine doses from Serum Institute

Bharat Biotech published the interim efficacy report of phase 3 clinical trial on its COVID-19 vaccine, officially known as Covaxin. The indigenous COVID-19 vaccine is found to be 81 per cent effective in preventing the virus

Government data shows that only 10% of about 12.6 million people immunised in India have taken the COVAXIN shot, which was found to be 81% effective in an interim analysis of the late-stage trial, its developer Bharat Biotech said

The sudden announcement came as a bolt out of the blue as earlier Sasikala said that she would remain active in politics after completion of her jail term

Digital media norms to be administered by Centre, not states The Information and Broadcasting (I&B) Ministry on Wednesday issued memorandum to states and union territories saying that the new rules for digital news publishers and over-the-top (OTT) platforms are to be administered by the Centre, not the states. The government had notified the Information Technology (Intermediary Guidelines and Digital Media Ethics Codes) Rules, 2021 on February 25. Defence equipment sales to India sho...

The think tank also expressed apprehensions that the world's largest democracy is moving towards authoritarianism under the NDA government headed by Prime Minister Narendra Modi

Krishna Ella, Chairman of Bharat Biotech had earlier said the company is focusing on the intranasal vaccine as the existing vaccines require two-dose intramuscular injections and a country like India needs 2.6 billion syringes and needles which may add up to pollution

Very early this morning, our first half a million doses of the AstraZeneca-Oxford vaccine from the Serum Institute arrived in Canada, said Prime Minister Justin Trudeau

So far, the Pfizer-BioNTtech and Moderna vaccines, made through a novel platform technology never used in humans before, are proven to have maximum efficacy

Catch top stories from the world of business and economy with BusinessToday.In's Biz EOD report

Meanwhile, consulting and processing services provider Accenture also said that it will cover the cost for employees and dependents eligible for vaccination.

The interim efficacy trend of 81 per cent, analysed as per the protocol approved by the Drugs Controller General of India, puts it at par with other global front-runner vaccines, stated ICMR

Data from 25,800 participants who received a vaccine or placebo in 1:1 ratio showed that the vaccine was well-tolerated; Bharat Biotech said the trial conducted with ICMR was the largest in India

Union Health Minister Dr. Harsh Vardhan has said citizens can get vaccinated according to their convenience

As senior citizens across the country take part in the vaccination drive, here is all the information they need two know about the two vaccines - Covaxin and Covishield

Phase 2 of COVID-19 vaccination commenced from Monday for those over 60 years of age and for people aged 45 and above with specified co-morbid conditions

Expect domestic air passenger traffic to return pre-COVID level by 2022-23, says ICRAExpecting domestic air passenger traffic to return to the pre-COVID-19 level by the financial year 2022-23 and international by 2023-24, rating agency ICRA on Monday said there could be a delay in the commercialisation of expanded capacity by 9-12 months. ICRA also said the cargo volumes are likely to grow around 36 per cent in 2021-22 and six per cent in 2022-23 after a 25 per cent contraction this fiscal, ...

\"People are dying in poor countries,\" Ngozi Okonjo-Iweala, new chief of WTO, said on her first day in office